We live in challenging times. COVID-19 has been a wakeup call, testing the status quo for the pharmaceutical industry and contract manufacturers. There is no shortage of news and emotional editorials about potential disruption of global supply chains and dependency on manufacturers outside of the U.S. Even though these topics have been front and center of our attention, it is important to assess the robustness of our supply chains and all manufacturers within them, regardless on which tectonic plate they reside.

Major themes:

• Biomedical Innovation Spurred by COVID-19
• CDMO Selection Criteria
• Considerations for ‘Cultural Fit’